Prothena Corporation plc · NASDAQ:PRTA

Prothena — Investor Presentation (June 2025)

47 slides from Prothena's investor presentation, Jun 15, 2025

  1. Slide 1: Corporate Overview June 2025

    CORPORATE OVERVIEW June 2025

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things, the sufficiency of our cash position to fund advancement of a broad pipeline; the continued advancement of our pipeline, and expected milestones in 2025, 2026, 2027, and beyo

  3. Slide 3: Our Mission Today

    Our Mission Today We are Focused on Delivering Life-Saving Therapies… …for unmet medical needs caused by diseases of protein dysregulation 3

  4. Slide 4: Addressing Devastating Proteinopathies Affecting Millions of Patients

    We are Addressing Devastating Proteinopathies Affecting Millions of Patients and Families Worldwide NEURODEGENERATIVE DISEASES RARE PERIPHERAL AMYLOID Transthyretin Alzheimer’s Parkinson’s amyloidosis disease (AD) disease (PD) (ATTR) >80 million >10 million 450,000 People worldwide living with Peopl

  5. Slide 5: Our Biology-Directed Engine Propels Prothena's Progress

    Our Biology-Directed Engine Propels Prothena’s Progress Across our Broad Pipeline Therapeutics engineered to optimally eliminate pathogenic proteins while preserving normal biology Disease- Driven Multiple Clinical Programs Ongoing Antibody One partnered Phase 3 program Engineering Product Deep cand

  6. Slide 6: Robust R&D Pipeline

    Robust R&D Pipeline PROGRAM/ GLOBAL PROTEIN TARGET DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 INDICATION PARTNER3 Prasinezumab -Synuclein Roche to initiate Phase 3 development Parkinson’s disease (C-terminus) Coramitug (PRX004) Transthyretin Phase 2 ATTR-CM ODD1 (misTTR) BMS-986446 (PRX005) Tau

  7. Slide 7: Potential Value-Creating Milestones

    Potential Value-Creating Milestones Up to $105 Million in Clinical Milestones1 in 2026 PRX012 Coramitug PRX019 BMS-986446 Prasinezumab P1 ASCENT Results of Completion of Completion of Completion of initial data P2 trial ongoing P1 trial ongoing P2 trial P3 development (August 2025) (2H 2025) (2026)

  8. Slide 8: Prothena Partnerships Expected to Generate Meaningful Value

    Prothena Partnerships Expected to Generate Meaningful Value Across Programs Up to $755 Million in Up to $1.23 Billion in Up to $1.55 Billion in Total Milestones + Royalties Total Milestones Total Milestones Across Two Clinical Stage Programs +Royalties ✓ Upfront Payment + Equity: $150 million2 Prasi

  9. Slide 9: Alzheimer's Disease

    Alzheimer’s Disease

  10. Slide 10: Our Team has Pioneered Multiple Scientific Advances in Protein Dysregulation

    Our Team has Pioneered Multiple Scientific Advances in Protein Dysregulation OUR LEGACY INCLUDES FOUNDATIONAL DISCOVERIES IN THE UNDERSTANDING OF ALZHEIMER’S DISEASE Pioneered fundamental discoveries elucidating the roles of beta amyloid (A), gamma secretase and beta secretase play in disease1 Firs

  11. Slide 11: Our Legacy Drives Our Vision to Transform Alzheimer's Care

    Our Legacy Drives Our Vision to Transform the Care of Alzheimer’s Disease With unparalleled protein …We’re uniquely positioned to address Alzheimer’s dysregulation expertise… Disease with a best-in-class portfolio PRX012, anti-Aβ candidate with potential best-in-class, highly potent binding; designe

  12. Slide 12: Targeting Alzheimer's Where it Matters

    Targeting Alzheimer’s Where it Matters Aβ has been established as a disease modifying target Aβ plaque Vascular Aβ deposits (fibrils) in Alzheimer’s disease Microglia Reduction of Aβ plaque MTBR-Tau transmission associated with clinically Neurofibrillary meaningful slowing of tangles (NFT) disease p

  13. Slide 13: Today's Clinical Science Validates the Mechanism Designed by Our Team

    Today’s Clinical Science Validates the Mechanism Designed by Our Team Mean Difference from Placebo in Reduction of Amyloid Plaque1 and CDR-SB Progression Group Level Mean Difference Disease from Placebo on CDR Slowing of Progression Reduction of amyloid plaque Increase of amyloid plaque Group Level

  14. Slide 14: Targeting Alzheimer's Where it Matters

    Targeting Alzheimer’s Where it Matters CHANGING THE TREATMENT PARADIGM THROUGH OUR BIOLOGY-DIRECTED ENGINE Dynamic biomarkers of the Alzheimer’s pathological cascade1 14 1 Jack, Clifford et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade, 2010 NIH Public Access

  15. Slide 15: PRX012

    PRX012 Alzheimer’s Disease

  16. Slide 16: PRX012: Leading a Paradigm Shift in the Treatment of Alzheimer's Disease

    PRX012: Leading a Paradigm Shift in the Treatment of Alzheimer’s Disease 300+ iterative antibody design and optimization campaigns led to… Key Antibody Design Attributes HUMANIZED IgG1 monoclonal antibody with low immunogenicity TARGETS a key epitope at the N-terminus of Aβ protein HIGH AFFINITY AND

  17. Slide 17: Translating Patient Needs Into Antibody Engineering

    Translating Patient Needs Into Antibody Engineering PATIENT-CENTRIC DESIGN STRATEGY FOR PRX012 TARGET PROFILE ANTIBODY DESIGN ATTRIBUTES OUR MISSION Maintain From First Effectively clear soluble and • N-terminal directed Generation insoluble aggregated amyloid Improve patient outcomes • Full effecto

  18. Slide 18: PRX012: Promotes Comprehensive Clearance of Amyloid Plaques

    PRX012: Promotes Comprehensive Clearance of Amyloid Plaques and Neutralization of Oligomers Designed to target and clear toxic aggregated forms of Aβ Free/ dispersed Aggregated Microglia PRX012 Aβ plaque Aβ Forms PRX012 elicits microglial-mediated phagocytosis Both unmodified Aβ fibrils and Phagocyt

  19. Slide 19: PRX012 and Surrogate Demonstrate Equivalent Potent Binding Affinity for Aβ

    PRX012 and Surrogate Demonstrate Equivalent Potent Binding Affinity for Aβ Surface Plasmon Resonance (SPR) Affinity for Aβ Species Aβ Fibrils Compound Fibril/Plaque N3pE-Aβ 60 Slow off-rate (PRX012 & PRX012s) PRX012 0.070a >67b Response (RU) 40 PRX012s 0.054a >67b Fast biphasic off-rate (aducanumab)

  20. Slide 20: PRX012s Binds Aβ Protofibrils With Very High Affinity

    PRX012s Binds Aβ Protofibrils With Very High Affinity Surface Plasmon Resonance Antibody Relative Affinity (KD1) Aβ Protofibrils Lecanemab1 1.97 nM (Tucker et al., 2015) Lecanemab2 1.91 nM dissociation Slower PRX012s 0.0975 nM SPR Binding Kinetics Antibody dissociation ka1 (1/Ms) kd1 (1/s) KD1 Lecan

  21. Slide 21: PRX012s Induced Potent and Robust Clearance of Pyroglutamate-modified Aβ

    PRX012s Induced Potent and Robust Clearance of Pyroglutamate-modified Aβ PRX012s PRX012s Abeta Aβ Donanemab Donanemab 40 Reduction %%Reduction ofof N3pE N3pE 20 Study Conditions Post-mortem AD brain tissue (same donor used for Tissue all conditions) Treatment PRX012s, donanemab, or IgG1 isotype cont

  22. Slide 22: PRX012s Promotes Simultaneous Microglia-Mediated Phagocytosis of Aβ and N3pE-Aβ

    PRX012s Promotes Simultaneous Microglia-Mediated Phagocytosis of Aβ and N3pE-Aβ in Post-mortem Brain Tissue From AD Subjects Microglia (Iba1) Aβ N3pE-Aβ Merge Microglia Aβ N3pE-Aβ Merge hIgG1 PRX012s Microglia (Iba1: green) simultaneously phagocytose Aβ (red) and pyroglutamate-modified Aβ (AβpE3-42:

  23. Slide 23: PRX012 Phase 1 SAD Design

    PRX012 Phase 1 SAD Design Healthy Volunteer Cohorts Trial • Age 20 – 45 years Design 70 mg 200 mg • Phase 1, randomized 3:1, double-blind, placebo-controlled, n~8 n~8 single ascending dose trial (3:1) (3:1) • 1 subcutaneous dose of PRX012 or placebo • Evaluate the safety, tolerability, Early Alzheim

  24. Slide 24: PRX012 Phase 1 Multiple Dose Design

    PRX012 Phase 1 Multiple Dose Design Trial Overview1 Key Inclusion Dose Escalation: “A” and “B” Cohorts2,3 Dose Expansion Key Objectives Criteria • Evaluate the safety, 45 mg A Cohort (n~32) • Patients with tolerability, and SC 6X Q4W early AD immunogenicity 70 mg A Cohort (n~32) • Effect on brain •

  25. Slide 25: BMS-986446 (formerly PRX005)

    BMS-986446 (formerly PRX005) Alzheimer’s Disease Global Neuroscience Collaboration with Bristol Myers Squibb

  26. Slide 26: BMS-986446: Potential Best-in-Class anti-Tau antibody for Alzheimer's Disease

    BMS-986446: Potential Best-in-Class anti-Tau antibody for Alzheimer’s Disease Phase 2 Trial (NCT06268886): Ongoing BMS-986446 Alzheimer’s disease • Global, double-blind, placebo-controlled Current Status: Phase 2 • 310 participants with early AD Anti-Tau Mechanism of Action • Randomized, 3 arms (two

  27. Slide 27: BMS-986446: MTBR-Specific Anti-Tau Antibody

    BMS-986446: MTBR-Specific Anti-Tau Antibody BMS-986446, a differentiated tau antibody that targets an optimal tau region within the MTBR • Recent publications strongly suggest that tau appears to spread throughout the brain via synaptically-connected pathways1 • This propagation of pathology is thou

  28. Slide 28: BMS-986446 (PRX005): Superior in Blocking Cellular Internalization of Tau

    BMS-986446 (PRX005): Superior in Blocking Cellular Internalization of Tau and Downstream Neurotoxicity Compared to Other Anti-Tau Antibodies PRX005 blocks internalization of tau Repeats 1 and 2 defined as the strongest inhibitory regions in screening with cellular 100 internalization and neurotoxici

  29. Slide 29: (m)PRX005 Treatment Reduces Pathological Tau in Transgenic Mouse Model

    (m)PRX005 Treatment Reduces Pathological Tau and Ameliorates Behavioral Deficit in Transgenic Tau Mouse Model All values are mean ± SE (n=15-20) Reduction of tau pathological markers Delay of behavioral deficit *p<0.05 *p<0.05 pTau-199/202 in brainstem (% area) * * Chronic dosing start pTau-212 in b

  30. Slide 30: BMS-986446: TargetTau-1 Phase 2 Trial Design

    BMS-986446: TargetTau-1 Phase 2 Trial Design TargetTau-1 Trial Overview (NCT06268886)1 Key Inclusion Criteria Primary Endpoint • Ages 50 – 80 years Placebo • Change from baseline in brain tau deposition as measured • MCI due to AD or by tau PET at 76 weeks mild AD dementia Randomized BMS-986446 Seco

  31. Slide 31: PRX123

    PRX123 Alzheimer’s Disease

  32. Slide 32: Potential Best-in-class Dual Aβ/Tau Vaccine for Treatment & Prevention of AD

    Vaccine Constructs: Potential Best-in-class Dual Aβ/Tau Vaccine for the Treatment & Prevention of AD PROTHENA IS PIONEERING THE DEVELOPMENT OF DUAL Aβ/TAU VACCINE CANDIDATE PRX123 • Synergistic mechanism designed for increased efficacy over single-target vaccines Cleavage Site A MTBR of tau – Stron

  33. Slide 33: Desirable Attributes of Aβ/Tau Vaccines and Prothena's Design Strategies

    Desirable Attributes of Aβ/Tau Vaccines and Prothena’s Design Strategies Design Strategy Desirable Output • Linear peptides, proprietary ✓ Optimal antigen presentation RESPONSE cleavable linkers with persistent immune response 1 Antibody levels, balanced • Optimal carriers, immunization ✓ Overcomes

  34. Slide 34: Dual Aβ/Tau Vaccines Demonstrate Desirable Quantity, Quality and Safety

    Prothena’s Dual Aβ/Tau Vaccines Demonstrate Desirable Quantity, Quality and Safety Quantity Quality Safety Unable to induce measurable cytotoxic T-cell activity against Aβ and tau in Non-human primates (ELISpot) Prothena’s Dual Vaccine Positive Control Aβ Tau ✓ Epitope, affinity, Aβ clearance, ✓ Avo

  35. Slide 35: Prasinezumab

    Prasinezumab Parkinson’s Disease Worldwide Collaboration with Roche

  36. Slide 36: Prasinezumab: Potential First-in-Class Treatment for Parkinson's Disease

    Prasinezumab: Potential First-in-Class Treatment for Parkinson’s Disease Phase 2 Clinical Development Programs: Prasinezumab Parkinson’s Disease • First anti--synuclein antibody to slow progression on measures of PD Current Status: Roche to initiate P3 program • Consistent positive trends across mu

  37. Slide 37: α-Synuclein Pathology is Strongly Implicated in Parkinson's Disease

    -Synuclein Pathology is Strongly Implicated in Parkinson’s Disease Accumulation of -Synuclein Neuronal -Synuclein Dopaminergic neurodegeneration is a predominant Symptoms neuropathological feature and Biological or Clinical Measures Functional impairment follows the topological progression of dis

  38. Slide 38: Prasinezumab: α-Synuclein Immunotherapy

    Prasinezumab: -Synuclein Immunotherapy REDUCE NEURONAL TOXICITY AND PREVENT CELL-TO-CELL TRANSMISSION1 Diseased Neuron Protected Neuron -Synuclein as an extracellular target during pathogenesis Aggregated • Caudal-rostral staging, extracellular host-to-graft transfer, -Synuclein various propagati

  39. Slide 39: Prasinezumab: Clinical Development Program for Early Parkinson's Disease

    Prasinezumab: Clinical Development Program for Early Parkinson’s Disease Phase 2 PASADENA (NCT03100149) Phase 2b PADOVA (NCT04777331) • N=316, randomized 1:1:1 (1500 mg, 4500 mg, placebo), Q4W • N=586, randomized 1:1 (1500 mg, placebo), Q4W IV dosing for IV dosing for 52 weeks (Part 1), followed by

  40. Slide 40: Phase 2b PADOVA Trial Summary of Results

    Phase 2b PADOVA Trial Summary of Results PRASINEZUMAB IN EARLY PARKINSON’S DISEASE • First anti--synuclein antibody to slow progression on measures of PD ✓ Prasinezumab showed potential clinical effect in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01] and p=0

  41. Slide 41: Phase 2 PASADENA Trial Summary of Results

    Phase 2 PASADENA Trial Summary of Results PRASINEZUMAB IN EARLY PARKINSON’S DISEASE • First anti--synuclein antibody to slow progression on measures of PD ✓ Part 1: 35% less progression vs. placebo at 1 year on MDS-UPDRS Part III1 • Greater slowing of motor progression in subpopulations of individu

  42. Slide 42: PASADENA Open-Label Extension

    PASADENA Open-Label Extension PRASINEZUMAB CONTINUED TO SLOW PROGRESSION OF MOTOR DEFICITS IN EARLY-STAGE PD 4-year change from baseline on MDS UPDRS Part III OFF score1 PASADENA: Open-Label Extension Compared prasinezumab population with a propensity score-balanced cohort of real-world data (RWD) P

  43. Slide 43: PASADENA Open-Label Extension

    PASADENA Open-Label Extension PRASINEZUMAB CONTINUED TO SLOW PROGRESSION OF MOTOR DEFICITS IN EARLY-STAGE PD 4-year change from baseline on MDS UPDRS Part III ON score1 PASADENA: Open-Label Extension The data suggests that prasinezumab slowed the progression of motor deficits (MDS-UPDRS Part III ON

  44. Slide 44: Coramitug (formerly PRX004)

    Coramitug (formerly PRX004) ATTR Amyloidosis with Cardiomyopathy ATTR Business Acquired by Novo Nordisk

  45. Slide 45: Coramitug: Potential First-in-Class Treatment for ATTR-CM

    Coramitug (formerly PRX004): Potential First-in-Class Treatment for ATTR-CM Phase 2 Signal Detection Trial (NCT05442047): Coramitug Ongoing ATTR amyloidosis with • N = ~99 ATTR-CM patients, 3 arms cardiomyopathy (ATTR-CM) • Participants receive IV infusion Q4W of 10 mg/kg or Current Status: Phase 2

  46. Slide 46: Differentiated Mechanism for ATTR-CM

    Differentiated Mechanism for ATTR-CM NON-PATHOGENIC PATHWAY PATHOGENIC PATHWAY HEART Protein Misfolding Restrictive cardiomyopathy Heart failure PERIPHERAL NERVES Loss of sensation LIVER FREE MONOMER, SOLUBLE Loss of reflex TETRAMER AGGREGATE Muscle weakness AMYLOID FIBRILS Coramitug: Current Treatm

  47. Slide 47: Designed to Deplete Amyloid

    Designed to Deplete Amyloid SUMMARY OF PRECLINICAL EFFECTS OF mPRX004 mPRX004 (murine ✓ Inhibits fibril formation form of PRX004) ✓ Specifically binds to pathogenic TTR preclinical results:1 ✓ Reacts to amyloid deposits in multiple organs in both wtATTR and ATTRv patients ✓ Promotes in vivo ATTR amy

Prothena — Investor Presentation (June 2025) on 6ix